NEW YORK (GenomeWeb News) – BioFocus will offer its customers Activiomics' proteomics services for identifying novel biomarkers for diagnostics and targets for new drugs, the companies said today.

Under a strategic agreement, BioFocus will offer its customers Activiomics' Targeted In-depth QUAntification of cell Signaling, or TIQUAS, technology for proteomics studies in oncology, inflammation, and metabolic disease.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.